OncoCyte Corp reports results for the quarter ended in September - Earnings Summary

Insight Molecular Diagnostics

09/11/2021 22:49

* OncoCyte Corp  OCX.OQ  reported a quarterly adjusted loss
of 15 cents​​ per share for the quarter ended in September. The
mean expectation of five analysts for the quarter was for a loss
of 12 cents per share.
* Revenue rose 77.3% to $984.00 thousand from a year ago; 
analysts expected $1.76 million. 
* The mean earnings estimate of analysts had fallen by about 20%
in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* OncoCyte Corp shares had fallen by 0.3% this quarter and
gained 48.5% so far this year.
* The company reported a quarterly loss of $13.8 million.
* Wall Street's median 12-month price target for OncoCyte Corp
is $8.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated November 9 at 10:49 p.m.
 ​All figures in US dollars unless otherwise stated